IL219740A0 - Humanized antibodies aganist human il-22ra their preparation and pharmaceutical compositions containing them - Google Patents

Humanized antibodies aganist human il-22ra their preparation and pharmaceutical compositions containing them

Info

Publication number
IL219740A0
IL219740A0 IL219740A IL21974012A IL219740A0 IL 219740 A0 IL219740 A0 IL 219740A0 IL 219740 A IL219740 A IL 219740A IL 21974012 A IL21974012 A IL 21974012A IL 219740 A0 IL219740 A0 IL 219740A0
Authority
IL
Israel
Prior art keywords
human
preparation
pharmaceutical compositions
compositions containing
humanized antibodies
Prior art date
Application number
IL219740A
Other languages
English (en)
Original Assignee
Merck Serono Sa
Beckmann Roland
Johnson Leger Carolina
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41565648&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IL219740(A0) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Merck Serono Sa, Beckmann Roland, Johnson Leger Carolina filed Critical Merck Serono Sa
Publication of IL219740A0 publication Critical patent/IL219740A0/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Dermatology (AREA)
  • Zoology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pulmonology (AREA)
  • Physics & Mathematics (AREA)
  • Mycology (AREA)
  • Rheumatology (AREA)
  • Plant Pathology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
IL219740A 2009-11-19 2012-05-13 Humanized antibodies aganist human il-22ra their preparation and pharmaceutical compositions containing them IL219740A0 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP09176525 2009-11-19
US26299809P 2009-11-20 2009-11-20
PCT/EP2010/067332 WO2011061119A1 (en) 2009-11-19 2010-11-12 Humanized antibodies against human il-22ra

Publications (1)

Publication Number Publication Date
IL219740A0 true IL219740A0 (en) 2012-07-31

Family

ID=41565648

Family Applications (1)

Application Number Title Priority Date Filing Date
IL219740A IL219740A0 (en) 2009-11-19 2012-05-13 Humanized antibodies aganist human il-22ra their preparation and pharmaceutical compositions containing them

Country Status (20)

Country Link
US (1) US8545844B2 (enExample)
EP (1) EP2512511B1 (enExample)
JP (1) JP5818804B2 (enExample)
KR (1) KR20120098783A (enExample)
CN (1) CN102665759B (enExample)
AU (1) AU2010321047B2 (enExample)
BR (1) BR112012012003A2 (enExample)
CA (1) CA2778864C (enExample)
EA (1) EA021356B1 (enExample)
EC (1) ECSP12011980A (enExample)
ES (1) ES2531996T3 (enExample)
IL (1) IL219740A0 (enExample)
IN (1) IN2012DN03362A (enExample)
MX (1) MX2012005791A (enExample)
NZ (1) NZ599438A (enExample)
PE (1) PE20121560A1 (enExample)
PH (1) PH12012500924A1 (enExample)
UA (1) UA105405C2 (enExample)
WO (1) WO2011061119A1 (enExample)
ZA (1) ZA201202793B (enExample)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2007004770A (es) * 2004-10-22 2007-11-22 Zymogenetics Inc Anticuerpos anti-il-22ra y moleculas y metodos para usarlos en inflamacion.
HUE039849T2 (hu) 2011-03-16 2019-02-28 Argenx Bvba CD70 elleni ellenanyagok
CN107318267B (zh) 2013-08-12 2021-08-17 豪夫迈·罗氏有限公司 用于治疗补体相关的病症的组合物和方法
PE20161440A1 (es) * 2014-05-01 2017-01-26 Genentech Inc Variantes del anticuerpo anti-factor d y sus usos
US10391168B1 (en) 2014-08-22 2019-08-27 University Of Bern Anti-CD70 combination therapy
WO2017075173A2 (en) 2015-10-30 2017-05-04 Genentech, Inc. Anti-factor d antibodies and conjugates
JP2018536650A (ja) 2015-10-30 2018-12-13 ジェネンテック， インコーポレイテッド 抗ｄ因子抗体変異体コンジュゲート及びその使用
ES2966133T3 (es) * 2016-03-18 2024-04-18 Staidson Beijing Biopharmaceuticals Co Ltd Proteína de fusión que comprende el factor de crecimiento nervioso y método de preparación y uso de la misma
GB201612337D0 (en) 2016-07-15 2016-08-31 Argen-X N V Ant-il-22r antibodies
EP3630182A4 (en) * 2017-05-24 2021-02-24 Development Center for Biotechnology HUMANIZED ANTIBODIES TO GLOBO H AND THEIR USE IN CANCER TREATMENT
KR102611853B1 (ko) 2017-06-30 2023-12-08 자임워크스 비씨 인코포레이티드 안정화된 키메라 fabs
GB201800649D0 (en) 2018-01-16 2018-02-28 Argenx Bvba CD70 Combination Therapy
WO2023232789A1 (en) * 2022-06-03 2023-12-07 Leo Pharma A/S Liquid formulation of il-22r antibody
WO2024184333A1 (en) 2023-03-08 2024-09-12 Leo Pharma A/S Il-22r antibody for use in treating atopic dermatitis

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5965704A (en) 1997-08-05 1999-10-12 Zymogenetics, Inc. Class two cytokine receptor-11
MX2007004770A (es) * 2004-10-22 2007-11-22 Zymogenetics Inc Anticuerpos anti-il-22ra y moleculas y metodos para usarlos en inflamacion.
KR20070114324A (ko) * 2005-03-25 2007-11-30 글리카트 바이오테크놀로지 아게 Ｍｃｓｐ 에 향하며 증가된 ｆｃ 수용체 결합 친화도 및효과기 작용을 갖는 항원 결합 분자
CA2631961A1 (en) * 2005-12-02 2007-11-08 Genentech, Inc. Compositions and methods for the treatment of diseases and disorders associated with cytokine signaling relating to antibodies that bind to il-22

Also Published As

Publication number Publication date
BR112012012003A2 (pt) 2016-11-29
ES2531996T3 (es) 2015-03-23
EP2512511B1 (en) 2015-01-07
EA021356B1 (ru) 2015-05-29
CA2778864A1 (en) 2011-05-26
ECSP12011980A (es) 2012-07-31
CN102665759B (zh) 2015-09-30
MX2012005791A (es) 2012-07-03
ZA201202793B (en) 2013-06-26
IN2012DN03362A (enExample) 2015-10-23
CA2778864C (en) 2017-06-27
AU2010321047A1 (en) 2012-05-24
WO2011061119A1 (en) 2011-05-26
PE20121560A1 (es) 2012-12-05
AU2010321047B2 (en) 2016-06-09
NZ599438A (en) 2013-12-20
PH12012500924A1 (en) 2012-11-26
EA201290360A1 (ru) 2012-11-30
CN102665759A (zh) 2012-09-12
JP2013511267A (ja) 2013-04-04
US20120230990A1 (en) 2012-09-13
KR20120098783A (ko) 2012-09-05
UA105405C2 (ru) 2014-05-12
US8545844B2 (en) 2013-10-01
JP5818804B2 (ja) 2015-11-18
EP2512511A1 (en) 2012-10-24

Similar Documents

Publication Publication Date Title
IL219740A0 (en) Humanized antibodies aganist human il-22ra their preparation and pharmaceutical compositions containing them
IL265707A (en) Pharmaceutical preparations containing human antibodies to pcsk9
IL262649A (en) Soluble human ST – 2 antibodies and testing
IL253870B (en) Certain amino-pyrimidines and pharmaceutical preparations containing them
ZA201208265B (en) Pharmaceutical compositions and methods of making same
ZA201303175B (en) Human anti-tau antibodies
IL222329A0 (en) Antibodies that bind human cd27 and uses thereof
PT2750682T (pt) Composição compreendendo a flora intestinal cultivada anaerobiamente
PL2515941T3 (pl) Preparat farmaceutyczny zawierający bewacyzumab
IL222738A0 (en) Pharmaceutical emulsion composition comprising progestogen
LT2582728T (lt) Žmogaus antikūno vaisto konjugatai prieš audinių faktorių
PL2621955T3 (pl) Przeciwciała anty-CEACAM6 i ich zastosowania
ZA201307641B (en) Human tissue factor antibody and uses thereof
EP2542589A4 (en) ANTIBODIES AND COMPOSITIONS ANTI-HER2
ZA201209739B (en) Levocarrimycin,pharmaceutical compositions,preparation methods and uses thereof
IL230463A0 (en) Benzamides, their preparation and pharmaceutical preparations containing them
GB201302653D0 (en) Pharmaceutical compositions and methods of treatment
EP2797629A4 (en) AGLYCOSYLATED HUMAN ANTIBODY AND FUSION PROTEIN AND USES THEREOF
IL223292A (en) Human immunoglobulin stabilized preparation
EP2650367A4 (en) HUMAN MONOCLONAL ANTIBODY
IL216440A0 (en) Antibodies against human ccn1 and uses thereof
IL225823A0 (en) History of quinazoline, their preparation and pharmaceutical preparations containing them
PT2415463E (pt) Composição medicinal em partículas
IL225378A0 (en) History of phenylquinazoline, their preparation and pharmaceutical preparations containing them
IL226635B (en) Human anti-sod1 antibodies